GIANT CELL ARTERITIS
publications
“Title of publication” Journal, Year
Penn investigators involved (*lead)
What we learned
“A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis”
Arthritis & Rheumatology, 2017
Dr. Peter Merkel*
Dr. Antoine Sreih
“Infections and the risk of incident giant cell arteritis: a population-based, case-control study”
Annals of the Rheumatic Diseases, 2017
Dr. Rennie Rhee*
Dr. Peter Merkel
- Patients with GCA who received abatacept in addition to prednisone were less likely to relapse and had more months in remission
- Antecedent infections are modestly associated with the development of GCA